A new artificial intelligence-based cardiac imaging tool from Philips has received U.S. regulatory clearance, adding momentum to the broader shift toward AI-assisted workflows in radiology and cardiology. On March 6, 2026, Philips announced that the U.S. Food and Drug Administration granted 510(k) clearance to SmartHeart, an AI-powered cardiac magnetic resonance planning solution designed to automate one of the most technically challenging MRI exams in routine clinical care. According to Philips and follow-up industry coverage, the software is built to reduce exam complexity, improve consistency across operators, and help hospitals and imaging centers expand access to cardiac MR without adding the same level of specialized manual planning.
Cardiac MRI, often called cardiac MR or CMR, is one of the most advanced noninvasive imaging tools available for evaluating heart structure, function, perfusion, and tissue health. It is especially valuable in assessing cardiomyopathies, congenital heart disease, ischemic injury, myocarditis, and other structural or functional cardiac disorders. But despite its clinical value, cardiac MR has historically remained difficult to scale. The exam requires careful setup, detailed anatomical alignment, and repeated adjustments that depend heavily on operator experience. That complexity can lengthen scan preparation, create variability from one technologist to another, and limit the number of sites that can reliably perform high-quality cardiac MR. Philips is positioning SmartHeart as a direct response to those workflow barriers.
What happened here is significant because SmartHeart targets the planning stage of the scan itself. Philips said the software can automate 14 standard and advanced cardiac views in under 30 seconds, using AI trained on more than 1,200 cardiac MR datasets. That means the technology is designed not just to assist after images are captured, but to automate the actual preparation of the exam before acquisition begins. Becker’s reported that the tool is meant to simplify one of the most difficult MRI studies now performed in cardiology, while Cardiovascular Business emphasized that the platform is intended to increase productivity and make complex exams easier for less experienced technologists to perform. In market terms, that makes the clearance important not only as a product announcement, but as a signal that imaging AI is moving deeper into the operational core of how exams are run.
Why does this matter to the healthcare market? Because advanced imaging increasingly depends on operational efficiency as much as diagnostic performance. In many radiology and cardiology departments, demand for sophisticated imaging continues to rise while
staffing remains tight and workflow consistency is difficult to maintain. Cardiac MR is particularly exposed to these pressures because it often requires higher expertise than routine MRI studies. If a planning tool can reduce setup time and lower dependence on highly specialized operators, it may improve scanner utilization, support more predictable scheduling, and help departments offer advanced cardiac imaging more consistently. For hospitals and outpatient imaging centers, those improvements can influence equipment utilization, service-line growth, and the economics of imaging capacity.
The staffing dimension is one of the strongest parts of the story. Philips said SmartHeart is designed to reduce repetitive manual adjustments and minimize inter-operator variability. That could matter for facilities where advanced cardiac MRI is limited by the availability of a small number of highly experienced staff. A more automated workflow may allow less experienced technologists to perform exams with greater consistency, which in turn could widen access to cardiac MR beyond major academic centers. This does not eliminate the need for training or clinical oversight, but it may reduce one of the most important practical barriers to broader adoption. For imaging leaders, that is a meaningful value proposition in a labor-constrained environment.
There is also a patient experience angle. Philips said the technology can reduce the number of breath-holds required for basic cardiac views by up to 75%. That matters because repeated breath-holds are one of the harder parts of many cardiac MR studies, especially for patients with heart failure, arrhythmias, respiratory disease, anxiety, or pediatric conditions. Fewer breath-holds may improve comfort and reduce motion-related image problems, which can also help departments avoid repeated acquisitions and longer exam times. Even though these are manufacturer-reported performance claims, they point to a larger trend: imaging vendors are increasingly trying to show that AI can improve not only workflow efficiency, but also patient tolerance and exam reliability.
Another reason this clearance stands out is that SmartHeart appears to be part of a larger Philips strategy in AI-enabled cardiac imaging. Philips linked the planning tool to a broader cardiac MR ecosystem that includes motion correction, free-breathing capabilities, and perfusion quantification. That suggests the company is building an integrated workflow platform rather than marketing a single isolated feature. For procurement teams, that may matter because future imaging purchases are likely to focus more on platform value, automation depth, and interoperability across the care pathway. In that environment,
